Reuters logo
BRIEF-Vertex says FDA sets action date of Feb 28, 2018 for its Tezacaftor/Ivacaftor Combination Treatment
2017年8月24日 / 下午3点40分 / 3 个月前

BRIEF-Vertex says FDA sets action date of Feb 28, 2018 for its Tezacaftor/Ivacaftor Combination Treatment

Aug 24 (Reuters) - Vertex Pharmaceuticals Inc:

* Vertex announces acceptance of its applications for review of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis by the FDA and EMA

* ‍FDA grants Priority Review of application and sets action date of February 28, 2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below